Integra LifeSciences to Announce Q1 Earnings on May 5
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Source: seekingalpha
- Earnings Announcement Schedule: Integra LifeSciences Holdings Corporation (IART) is set to announce its Q1 2023 earnings on May 5 before market open, with consensus EPS estimate at $0.40, reflecting a 2.4% year-over-year decline, and revenue estimate at $381.77 million, down 0.2% year-over-year.
- Historical Performance Review: Over the past two years, IART has surpassed EPS estimates 75% of the time and revenue estimates 75% of the time, indicating a strong track record of financial performance and market confidence.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen no upward revisions and seven downward revisions, while revenue estimates have experienced one upward revision and four downward revisions, reflecting a cautious market outlook on the company's future performance.
- Long-term Target Outlook: Integra LifeSciences has set a revenue target of $1.66 billion to $1.7 billion for 2026, indicating that the company is undergoing a transformation through a new operating model to drive future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IART?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IART
Wall Street analysts forecast IART stock price to fall
6 Analyst Rating
0 Buy
2 Hold
4 Sell
Moderate Sell
Current: 16.460
Low
10.00
Averages
12.33
High
14.00
Current: 16.460
Low
10.00
Averages
12.33
High
14.00
About IART
Integra LifeSciences Holdings Corporation is a global medical technology company. It manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Four High-Growth GARP Stocks for 2026
- DaVita's Growth Potential: DaVita, a leading provider of dialysis services in the U.S., demonstrated strong momentum in Q1 2026 with an impressive long-term growth rate of 20.2%, making it an ideal GARP investment choice due to its reasonable PEG and P/E ratios, showcasing sustainable profitability.
- Integra's Market Demand: Integra LifeSciences leads in regenerative medicine, with a projected five-year growth rate of 5.9% for 2026, as steady demand in neurosurgery and ENT products highlights the company's strong competitive position in the medical device market.
- Braskem's Industry Position: Braskem manufactures petrochemical products in Brazil and internationally, with an expected long-term growth rate of 16.8%, and its superior value and growth scores make it stand out in GARP investment strategies, reflecting robust performance in the global market.
- LyondellBasell's Historical Growth: LyondellBasell holds a significant position in the global plastics and chemicals industry, boasting a historical growth rate of 49.4%, and its reasonable PEG and P/E ratios position it as a preferred choice for GARP investors, demonstrating strong market potential.
See More
Conexeu Sciences Inc. Begins Trading on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking a significant advancement for the preclinical-stage company centered around its CXU™ bioregenerative platform, which is expected to attract more investment for product development.
- Innovative Platform: The CXU™ is a patented bioregenerative extracellular matrix designed to restore soft tissue lost due to injury, aging, and GLP-1-related weight loss, with its first product, Ten Minute Tissue™, demonstrating enhanced healing dynamics and a low inflammatory profile in preclinical studies, potentially garnering significant market interest.
- Market Outlook: Conexeu enters a public market that is showing genuine commercial momentum, with competitors like Integra LifeSciences and Bioventus exceeding expectations in recent earnings reports, indicating strong demand in the regenerative medicine sector, and the listing is likely to enhance Conexeu's market share.
- Strategic Positioning: The listing not only provides Conexeu with the opportunity for capital formation but also enables the advancement of the CXU™ platform across multiple product lines, with plans to submit a 510(k) application in early 2027, further solidifying its position in the regenerative medicine field.
See More
Conexeu Sciences Inc. Successfully Debuts on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking its entry into public markets as a regenerative tissue platform company, which is expected to drive business growth in wound care and aesthetic medicine sectors.
- Platform Advantage: The company's CXU™ extracellular matrix platform is designed to scale across multiple markets without reformulation, a structural advantage that sets it apart from early-stage regenerative medicine companies and may lay the groundwork for future market share expansion.
- Innovative Reconstruction Method: Conexeu's B.R.E.A.S.T.™ matrix is a 3D bioprinted scaffold designed to support the body's own tissue regeneration rather than serve as a permanent implant, representing a potential paradigm shift for over 100,000 U.S. women undergoing mastectomies annually.
- Intellectual Property Protection: Conexeu holds issued patents across the U.S., E.U., Japan, and Australia with no royalty or licensing obligations, providing the freedom to expand into new indications and potentially accelerating its 510(k) submission process.
See More
Integra LifeSciences Q1 2026 Earnings Highlights
- Leadership Transition: Stuart Essig returns as CEO while appointing Mike McBreen as Chief Commercial Officer, aiming to enhance commercial execution and maintain ongoing transformation strategies, thereby strengthening the company's competitive position in the medical device market.
- Strong Financial Performance: The first quarter total revenue reached $392 million with adjusted earnings per share of $0.54, both exceeding expectations, reflecting solid product demand and improved supply execution, with full-year revenue guidance maintained at $1.66 billion to $1.7 billion.
- Optimistic Outlook: The company expects second-quarter revenues to range from $410 million to $425 million and adjusted earnings per share between $0.44 and $0.52, demonstrating confidence in future growth while planning to start production at the Braintree facility by the end of June.
- Market Opportunities: The PMA for SurgiMend and DuraSorb is anticipated to be approved in 2027, indicating a strategic positioning in the rapidly growing $800 million implant-based breast reconstruction market.
See More
Integra LifeSciences Q1 Earnings Exceed Expectations
- Earnings Beat: Integra LifeSciences reported a Q1 non-GAAP EPS of $0.54, exceeding expectations by $0.14, which reflects a significant improvement in profitability and boosts investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $391.9 million, a 2.4% year-over-year increase, surpassing market expectations by $10.13 million, indicating robust performance in the medical device sector.
- Margin Improvement: The adjusted gross margin rose to 64.1% from 62.2% in the prior year, demonstrating successful cost control and product mix optimization, which further enhances profitability.
- Guidance Update: Integra reaffirmed its full-year revenue guidance for 2026 at $1.662 billion to $1.702 billion and raised its adjusted EPS forecast to a range of $2.40 to $2.50, reflecting strong confidence in future performance.
See More
Integra LifeSciences Appoints New CEO
- Executive Change: Integra LifeSciences announced that Stuart Essig, the chairman of the board, will become the CEO effective May 1, 2026, succeeding Mojdeh Poul, who is pursuing other opportunities, indicating a strategic shift in leadership.
- Extensive Experience: Essig brings over 30 years of experience in the medical technology and healthcare sectors and will continue as chairman, expected to leverage his industry knowledge to drive future growth and enhance market competitiveness.
- Financial Targets: Integra LifeSciences has set a revenue target of $1.66 billion to $1.7 billion for 2026, reflecting the company's transformation strategy under a new operating model aimed at improving overall performance and shareholder value.
- Market Reaction: This appointment may positively impact investor confidence, especially against the backdrop of significant company transformation, with Essig's leadership seen as crucial to achieving financial objectives.
See More
Four High-Growth GARP Stocks for 2026
- DaVita's Growth Potential: DaVita, a leading provider of dialysis services in the U.S., demonstrated strong momentum in Q1 2026 with an impressive long-term growth rate of 20.2%, making it an ideal GARP investment choice due to its reasonable PEG and P/E ratios, showcasing sustainable profitability.
- Integra's Market Demand: Integra LifeSciences leads in regenerative medicine, with a projected five-year growth rate of 5.9% for 2026, as steady demand in neurosurgery and ENT products highlights the company's strong competitive position in the medical device market.
- Braskem's Industry Position: Braskem manufactures petrochemical products in Brazil and internationally, with an expected long-term growth rate of 16.8%, and its superior value and growth scores make it stand out in GARP investment strategies, reflecting robust performance in the global market.
- LyondellBasell's Historical Growth: LyondellBasell holds a significant position in the global plastics and chemicals industry, boasting a historical growth rate of 49.4%, and its reasonable PEG and P/E ratios position it as a preferred choice for GARP investors, demonstrating strong market potential.
See More
Conexeu Sciences Inc. Begins Trading on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking a significant advancement for the preclinical-stage company centered around its CXU™ bioregenerative platform, which is expected to attract more investment for product development.
- Innovative Platform: The CXU™ is a patented bioregenerative extracellular matrix designed to restore soft tissue lost due to injury, aging, and GLP-1-related weight loss, with its first product, Ten Minute Tissue™, demonstrating enhanced healing dynamics and a low inflammatory profile in preclinical studies, potentially garnering significant market interest.
- Market Outlook: Conexeu enters a public market that is showing genuine commercial momentum, with competitors like Integra LifeSciences and Bioventus exceeding expectations in recent earnings reports, indicating strong demand in the regenerative medicine sector, and the listing is likely to enhance Conexeu's market share.
- Strategic Positioning: The listing not only provides Conexeu with the opportunity for capital formation but also enables the advancement of the CXU™ platform across multiple product lines, with plans to submit a 510(k) application in early 2027, further solidifying its position in the regenerative medicine field.
See More
Conexeu Sciences Inc. Successfully Debuts on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking its entry into public markets as a regenerative tissue platform company, which is expected to drive business growth in wound care and aesthetic medicine sectors.
- Platform Advantage: The company's CXU™ extracellular matrix platform is designed to scale across multiple markets without reformulation, a structural advantage that sets it apart from early-stage regenerative medicine companies and may lay the groundwork for future market share expansion.
- Innovative Reconstruction Method: Conexeu's B.R.E.A.S.T.™ matrix is a 3D bioprinted scaffold designed to support the body's own tissue regeneration rather than serve as a permanent implant, representing a potential paradigm shift for over 100,000 U.S. women undergoing mastectomies annually.
- Intellectual Property Protection: Conexeu holds issued patents across the U.S., E.U., Japan, and Australia with no royalty or licensing obligations, providing the freedom to expand into new indications and potentially accelerating its 510(k) submission process.
See More
Integra LifeSciences Q1 2026 Earnings Highlights
- Leadership Transition: Stuart Essig returns as CEO while appointing Mike McBreen as Chief Commercial Officer, aiming to enhance commercial execution and maintain ongoing transformation strategies, thereby strengthening the company's competitive position in the medical device market.
- Strong Financial Performance: The first quarter total revenue reached $392 million with adjusted earnings per share of $0.54, both exceeding expectations, reflecting solid product demand and improved supply execution, with full-year revenue guidance maintained at $1.66 billion to $1.7 billion.
- Optimistic Outlook: The company expects second-quarter revenues to range from $410 million to $425 million and adjusted earnings per share between $0.44 and $0.52, demonstrating confidence in future growth while planning to start production at the Braintree facility by the end of June.
- Market Opportunities: The PMA for SurgiMend and DuraSorb is anticipated to be approved in 2027, indicating a strategic positioning in the rapidly growing $800 million implant-based breast reconstruction market.
See More
Integra LifeSciences Q1 Earnings Exceed Expectations
- Earnings Beat: Integra LifeSciences reported a Q1 non-GAAP EPS of $0.54, exceeding expectations by $0.14, which reflects a significant improvement in profitability and boosts investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $391.9 million, a 2.4% year-over-year increase, surpassing market expectations by $10.13 million, indicating robust performance in the medical device sector.
- Margin Improvement: The adjusted gross margin rose to 64.1% from 62.2% in the prior year, demonstrating successful cost control and product mix optimization, which further enhances profitability.
- Guidance Update: Integra reaffirmed its full-year revenue guidance for 2026 at $1.662 billion to $1.702 billion and raised its adjusted EPS forecast to a range of $2.40 to $2.50, reflecting strong confidence in future performance.
See More
Integra LifeSciences Appoints New CEO
- Executive Change: Integra LifeSciences announced that Stuart Essig, the chairman of the board, will become the CEO effective May 1, 2026, succeeding Mojdeh Poul, who is pursuing other opportunities, indicating a strategic shift in leadership.
- Extensive Experience: Essig brings over 30 years of experience in the medical technology and healthcare sectors and will continue as chairman, expected to leverage his industry knowledge to drive future growth and enhance market competitiveness.
- Financial Targets: Integra LifeSciences has set a revenue target of $1.66 billion to $1.7 billion for 2026, reflecting the company's transformation strategy under a new operating model aimed at improving overall performance and shareholder value.
- Market Reaction: This appointment may positively impact investor confidence, especially against the backdrop of significant company transformation, with Essig's leadership seen as crucial to achieving financial objectives.
See More
